Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity
66,67 Clinical Management and Risk Mitigation Effective risk mitigation requires assessment of baseline psychiatric history, proactive patient counselling, and ongoing clinical monitoring
The choice depends on the type, severity, and duration of pain, as well as individual patient factors
It has a strong antioxidant effect, supports metabolism and contributes to the oxidation of fats, and additionally supports mental and physical abilities and affects well-being and concentration
US$ 28.12
US$ 25.84
US$ 24.23
US$ 22.58
